Literature DB >> 9618006

Evidence that dark-phase hyperphagia induced by neurotoxin 6-hydroxydopamine may be due to decreased leptin and increased neuropeptide Y signaling.

P S Kalra1, M G Dube, B Xu, W G Farmerie, S P Kalra.   

Abstract

Hyperphagia and obesity can be experimentally induced in rodents by microinjection of 6-hydroxydopamine (6-OHDA) into the ventral noradrenergic bundle (VNAB) to interrupt efferent catecholaminergic pathways to the hypothalamus. Since hypothalamic neuropeptide Y (NPY) is implicated in the control of ingestive behavior, we evaluated hypothalamic NPY activity in this model of obesity. Adult male rats injected bilaterally with 12 microg of 6-OHDA in the VNAB displayed an enhanced rate of body weight gain and selective dark-phase hyperphagia that started at about 10 days postinjection and persisted for the entire duration of the experiment. NPY gene expression, assessed by ribonuclease protection assay, was significantly higher in the hypothalami of 6-OHDA-treated hyperphagic rats during the dark phase (p < 0.01 vs. levels during the light phase and in control, vehicle-injected rats). We also evaluated gene expression of NPY Y and Y5 receptors, receptor subtypes reported to mediate NPY-induced feeding. The dark-phase increase in NPY mRNA was accompanied by the concomitant upregulation of NPY Y5R gene expression, but not of Y1R mRNA levels. Leptin, the peripheral hormone secreted by adipocytes, is believed to maintain body weight and inhibit food intake, most likely by suppressing hypothalamic NPY activity. Evaluation of leptin gene expression in the epididymal fat revealed that the upregulation of leptin mRNA noted during the dark phase in control rats did not occur in 6-OHDA-treated rats. These observations implied that the normal restraint on NPY and feeding exercised by leptin in control rats may be abrogated in 6-OHDA-treated hyperphagic rats due to insufficient levels of leptin. If so, administration of leptin should inhibit food intake in these rats. Indeed, injection of leptin (2 mg/kg, intraperitoneally (i.p.)) on 2 consecutive days reduced 24-h food intake by 25% and significantly reduced body weight. These results suggest that the nocturnal hyperphagia and resultant obesity induced by 6-OHDA injected into the VNAB may be attributed to leptin deficiency concomitant with increased hypothalamic NPY.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9618006     DOI: 10.1016/s0031-9384(97)00545-3

Source DB:  PubMed          Journal:  Physiol Behav        ISSN: 0031-9384


  6 in total

1.  Agmatine in the hypothalamic paraventricular nucleus stimulates feeding in rats: involvement of neuropeptide Y.

Authors:  B G Taksande; N R Kotagale; K T Nakhate; P D Mali; D M Kokare; K Hirani; N K Subhedar; C T Chopde; R R Ugale
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

Review 2.  Neuropeptide Y: a physiological orexigen modulated by the feedback action of ghrelin and leptin.

Authors:  Satya P Kalra; Pushpa S Kalra
Journal:  Endocrine       Date:  2003-10       Impact factor: 3.633

3.  Intracerebroventricular administration of C-type natriuretic peptide suppresses food intake via activation of the melanocortin system in mice.

Authors:  Nobuko Yamada-Goto; Goro Katsuura; Ken Ebihara; Megumi Inuzuka; Yukari Ochi; Yui Yamashita; Toru Kusakabe; Akihiro Yasoda; Noriko Satoh-Asahara; Hiroyuki Ariyasu; Kiminori Hosoda; Kazuwa Nakao
Journal:  Diabetes       Date:  2012-12-28       Impact factor: 9.461

Review 4.  Environmental exposure, obesity, and Parkinson's disease: lessons from fat and old worms.

Authors:  Layla Aitlhadj; Daiana Silva Avila; Alexandre Benedetto; Michael Aschner; Stephen Richard Stürzenbaum
Journal:  Environ Health Perspect       Date:  2010-08-25       Impact factor: 9.031

Review 5.  Chronopharmacology: new insights and therapeutic implications.

Authors:  Robert Dallmann; Steven A Brown; Frédéric Gachon
Journal:  Annu Rev Pharmacol Toxicol       Date:  2013-10-16       Impact factor: 13.820

6.  Neuropeptide Y in the noradrenergic neurons induces the development of cardiometabolic diseases in a transgenic mouse model.

Authors:  Suvi T Ruohonen; Ullamari Pesonen; Eriika Savontaus
Journal:  Indian J Endocrinol Metab       Date:  2012-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.